AOP Orphan, AOP Orphan IP AG and orphanix GmbH join forces to develop RetinolX to prevent bronchopulmonary dysplasia
Vienna (pts036/13.05.2019/13:30) – AOP Orphan IP AG and AOP Orphan Pharmaceuticals AG have entered into a partnership with orphanix GmbH to jointly develop RetinolX, an innovative medicine for the prevention of Bronchopulmonary Dysplasia (BPD). BPD is a life-threatening lung disease affecting very preterm infants. Around 1 % of births are very preterm and potentially affected … Skaityti toliau